Across the 11 pediatric pan-cancer studies, DIS3L2 was on the analysis panel for 2,786 patients (Supplementary Data 16–26), reporting one LoF variant83 in a child with WT (Supplementary Data 5–15). This evidence concerns the gene DIS3L2 and cancer.